Luxembourg, Oct. 13 -- The European Investment Bank (EIB) and the European Commission (EC) are teaming up with BioNTech to help advance a messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda. To support this project, BioNTech has been awarded a blended financing option of up to €95 million: a €35 million Commission grant, and the possibility to take out a loan of up to €60 million from the EIB. The facility is designed to produce mRNA vaccines for diseases that matter most to Africa - such as malaria, tuberculosis, HIV, and mpox - if successfully developed and approved. The facility will use BioNTech's "BioNTainers"-high-tech, modular units that can quickly be set up and adapted to produce different mRNA v...